Open Access Short Report

Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer

Rhizlane Belbaraka12*, Olivier Trédan1, Isabelle Ray-Coquard1, Giselle Chvetzoff1, Agathe Bajard3, David Pérol1, Nabil Ismaili2, Mohammed Ismaili4, Hassan Errihani2, Thomas Bachelot1 and Paul Rebattu1

Author Affiliations

1 Department of Medical Oncology, Centre Léon-Bérard, 28 Rue Laennec, Lyon-69008, France

2 Department of Medical Oncology, National Institute of Oncology, Rabat-10000, Morocco

3 Department of Biostatistics, Centre Léon-Bérard, 28 Rue Laennec, Lyon-69008, France

4 Department of Microbiology, Moulay Ismail University, Meknes-50000, Morocco

For all author emails, please log on.

BMC Research Notes 2010, 3:164  doi:10.1186/1756-0500-3-164

Published: 10 June 2010



Little is known about prognosis of metastatic patients after receiving a first-line treatment and failure. Our group already showed in pre-treated patients enrolled in phase I clinical trials that a performance status (PS) > 2 and an LDH > 600 UI/L were independent prognostic factors. In this prospective study, which included 45 patients, we identified clinical and biological variables as outcome predictors in metastatic Non-Small Cell lung cancer after first line chemotherapy were identified.


Forty-five patients that were previously treated for metastatic disease from 12/2000 to 11/2005 in the comprehensive cancer centre (Centre Léon Bérard). Clinical assessment and blood parameters were recorded and considered. Patient prognostic factors for overall survival (OS) with a 0.05-significance level in univariate analysis were entered in a multivariate Cox model for further analysis.

Patients' median age was 58.5 years (range: 37 - 76). Sixty two percent of the patients were PS = 0 or 1. After inclusion, nine patients received second-line (22.5%), and two received third-line chemotherapy (5%). Univariate analysis showed that the factors associated with reduced OS were: PS > 2, weight loss >10%, more than one line of chemotherapy treatment and abnormal blood parameters (hemoglobin (Hb), platelet and neutrophils counts). Multiple regression analysis confirmed that PS > 2 and abnormal hemoglobin were independent predictors for low overall survival. According to the presence of none (33%), 1 (37%) and 2 (30%) prognostic factors, median OS were 12, 5 and 2 months respectively.


From this prospective study, both PS and anemia were found as independent determinants of survival, we found that both PS and anemia were independent determinants of survival. The combination of poor PS and anemia is an effective strategy to predict survival in the case of patients with metastatic NSCLC receiving further treatment after the first line.